Article

Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults.

Department of Medical Oncology, Centre Léon-Bérard, 69008 Lyon, France.
Critical reviews in oncology/hematology (Impact Factor: 4.05). 10/2009; 73(1):68-91. DOI: 10.1016/j.critrevonc.2009.09.005
Source: PubMed

ABSTRACT The incidence of prostate cancer increases with age, with a median age at diagnosis of 68 years. Owing to increased life expectancy, the management of prostate cancer in senior adult men (i.e., aged 70 years or older) represents an important public health concern and a major challenge for the future. No specific guidelines have previously been published on the management of prostate cancer in older men. The SIOG has developed a proposal of recommendations in this setting.
A systematic bibliographical search focused on screening, diagnostic procedures, treatment options for localised, locally advanced and metastatic prostate cancer in senior adults was performed. Specific aspects of the geriatric approach were emphasised, including evaluation of health status (nutritional, cognitive, thymic, physical and psycho-social) and screening for vulnerability and frailty. Attention was drawn to the consequences of androgen deprivation and complications of local treatment, mainly incontinence. The collected material has been reviewed and discussed by a scientific panel including urologists, radiation oncologists, medical oncologists and geriatricians from both Europe and North America.
The consensus is to use either European Association of Urology or National Comprehensive Cancer Network clinical recommendations for prostate cancer treatment and to adapt them to health status based on instrumental activities of daily living (IADL) and activities daily living (ADL), comorbidity evaluation by Cumulative Illness Scoring Rating-Geriatrics and screening for malnutrition. Patients in Group 1 (no abnormality) are 'fit' and should receive the same treatment as younger patients; patients in Group 2 (one impairment in IADL or one uncontrolled comorbidity or at risk of malnutrition) are 'vulnerable' and should receive standard treatment after medical intervention; patients in Group 3 (one impairment in ADL or more than one uncontrolled comorbidity or severe malnutrition) are 'frail' and should receive adapted treatment; patients in Group 4 (dependent) should receive only symptomatic palliative treatment.
Treatment of prostate cancer in senior adults should be adapted to health status. Specific prospective studies in this setting are warranted.

0 Followers
 · 
211 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Geriatric oncology guidelines state that fit older men with prostate cancer should receive curative treatment. In a population-based study, we investigated associations between age and non-receipt of curative treatment in men with localised prostate cancer, and the effect of clinical variables on this in different age groups. Methods: Clinically localised prostate cancers (T1–T2N0M0) diagnosed from 2002 to 2008 among men aged ⩾40 years, with hospital in-patient episode(s) within 1 year post-diagnosis, were included (n=5456). Clinical and socio-demographic variables were obtained from cancer registrations. Comorbidity was determined from hospital episode data. Logistic regression was used to investigate associations between age and non-receipt of treatment, adjusting for confounders; the outcome was non-receipt of curative treatment (radical prostatectomy or radiotherapy). Results: The percentage who did not receive curative treatment was 9.2%, 14.3%, 48.2% and 91.7% for men aged 40–59, 60–69, 70–79 and 80+ years, respectively. After adjusting for clinical and socio-demographic factors, age remained the main determinant of treatment non-receipt. Men aged 70–79 had a significant five-fold increased risk of not having curative treatment compared with men aged 60–69 (odds ratio (OR)=5.5; 95% confidence interval 4.7, 6.5). In age-stratified analyses, clinical factors had a higher weight for men aged 60–69 than in other age strata. Over time, non-receipt of curative treatment increased among men aged 40–59 and decreased among men aged 70–79. Conclusion: Age remains the dominant factor in determining non-receipt of curative treatment. There have been some changes in clinical practice over time, but whether these will impact on prostate cancer mortality remains to be established.
    British Journal of Cancer 05/2013; 109(1). DOI:10.1038/bjc.2013.268 · 4.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Das Management des Prostatakarzinoms im hohen Alter wird kontrovers diskutiert. Die aktuellen Leitlinien empfehlen eine Diagnostik und Therapie des Prostatakarzinoms nur bei Patienten mit einer Lebenserwartung von > 10 Jahren. Hierbei spielen insbesondere im Alter die Komorbiditäten des Patienten eine entscheidende Rolle. Im klinischen Alltag beeinflusst jedoch oftmals alleine das tatsächliche Alter des Patienten die Therapieentscheidung. Eine leitlinienbasierte Therapie des Prostatakarzinoms sollte jedoch auch älteren Patienten angeboten werden. Die Therapieentscheidung orientiert sich hierbei zum einen am Gesundheitszustand des Patienten sowie am onkologischen Risiko. Die Einordnung des individuellen Gesundheitszustands kann anhand der vorliegenden Komorbiditäten, des Ernährungszustands und des Performance-Status bestimmt werden. Um eine optimale Therapie auch im hohen Alter zu gewährleisten, muss die onkologische Risikostratifizierung in die differentialtherapeutischen Überlegungen mit einfließen. Das Ziel dieses Artikels ist es, eine Übersicht über die Risikostratifizierung sowie Therapieoptionen des lokalisierten und metastasierten Prostatakarzinoms im Alter zu geben.
    Der Urologe 06/2013; 52(6). DOI:10.1007/s00120-013-3152-2 · 0.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hauptrisikofaktor für das Auftreten maligner Erkrankungen ist das Alter. Dies trifft auch auf die meisten Krebserkrankungen des Urogenitaltrakts zu. Zusammen mit dem demographischen Wandel in Deutschland und den meisten anderen Ländern wird daher die Zahl alter Patienten mit Krebserkrankungen des Urogenitaltrakts deutlich zunehmen. Onkologische Therapien sind mit Risiken für unerwünschte Wirkungen behaftet. Altern ist ein sehr heterogen verlaufender Prozess. Das chronologische Alter eines Patienten gibt seine individuellen Ressourcen, Defizite und Risiken nur unzureichend wieder. Systematisch werden sie durch ein geriatrisches Assessment erfasst. Die Integration des geriatrischen Assessments in onkologische Entscheidungsprozesse ist bisher unzureichend, aber eine wesentliche Aufgabe im Rahmen der Verbesserung der zukünftigen onkologischen Versorgung.
    Der Urologe 06/2013; 52(6). DOI:10.1007/s00120-013-3212-7 · 0.44 Impact Factor